Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis

被引:38
作者
Hosback, Sharah
Hardiman, Orla
Nolan, Catherine M.
Maria, A. C. Doyle B. B. B. A.
Gorman, Grainne
Lynch, Catherine
O'Toole, Orna
Jakeman, Philip [1 ]
机构
[1] Univ Limerick, Human Sci Res Unit, Limerick, Ireland
[2] Royal Coll Surgeons Ireland, Beaumont Hosp, Dept Neurol, Dublin 2, Ireland
[3] Univ Coll Dublin, Sch Biol Sci, Dublin 2, Ireland
基金
英国医学研究理事会;
关键词
IGF; amyotrophic lateral sclerosis; post polio syndrome; multiple sclerosis; interferon-beta;
D O I
10.1016/j.ghir.2007.06.002
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective: To provide a detailed profile of the peripheral IGF system in the neurological conditions; amyotrophic lateral sclerosis (ALS), post polio syndrome (PPS) and multiple sclerosis (MS). To determine whether subsets of patients within the disease groups could be identified in whom one or more components of the IGF regulatory system are altered compared to healthy control subjects matched for age. sex and BMI. Design: Three cohorts of patients were recruited, 28 with ALS, IS with PPS and 23 with MS. Patients were individually matched to a healthy control based on sex, age (+/- 3yr), and BMI (+/- 2.5 kg.m(-2)). The concentration (ng/ml) of serum IGF-I, IGF-II, IGFBP-1. IGFBP-2 and IGFBP-3 and acid-labile subunit (mu g/ml) was determined by IRMA. Results: In ALS patients, there was an increase of 11% in [IGF(TOTAL)] (p = 0.042) ([IGF(TOTAL)] = [IGF-I] + [IGF-II) and [IGFBP-1] was decreased by 34% (p = 0.050) compared to matched controls. In "surviving" ALS patients, defined as those ALS patients with long disease duration (+2 SD from the mean survival time for Irish patients post diagnosis), there was an increase in [IGF-I] 36% (p = 0.032) and a large decrease in [IGFBP-1] -58% (p = 0.020) compared to controls. These differences were not evident in pre-agonal ALS patients. The concentration of serum IGF-I was 38% (p = 0.018), acid-labile subunit 17% (p = 0.044) and IGFBP-2 43% (p = 0.035) higher in MS patients compared to controls. When stratified for interferon-beta (IFN-beta) use, we observed an increase in serum [IGF-I] 52% (p = 0.013) and [IGF(TOTAL)] 19% (p = 0.043) in MS patients undergoing IFN-beta treatment, but MS patients not undergoing IFN-beta treatment had similar IGF and IGFBP concentration to controls. Serum [IGFBP-3] 18% (p = 0.033), [IGFBP-2] 86% (p = 0.015) and (acid-labile subunit) 33% (p = 0.012) was also higher in IFN-beta patients compared to controls. Stratified by stage of disease the most significant increase in components of the peripheral IGF system was attributed to relapsing-remitting MS patients treated with IFN-beta. All components of the peripheral IGF system in PPS patients were similar to controls. Conclusions: The increase in circulating IGF-I and a reduction in regulatory binding protein IGFBP-1 in ALS patients with a "stable" disease profile suggest a potential change in peripheral IGF bioavailability in these subjects. In MS, we report a change in a number of components of the peripheral IGF system, the observed increase in IGF-I in patients treated with IFN-beta being of most significance as a potential therapeutic biomarker. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:472 / 479
页数:8
相关论文
共 40 条
  • [1] Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities
    Baxter, RC
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2000, 278 (06): : E967 - E976
  • [2] Inhibition of the insulin-like growth factor (IGF)-IFG-binding protein interaction
    Baxter, RC
    [J]. HORMONE RESEARCH, 2001, 55 : 68 - 72
  • [3] BLAND M, 2000, INTRO MED STAT, V226
  • [4] A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis
    Borasio, GD
    Robberecht, W
    Leigh, PN
    Emile, J
    Guiloff, RJ
    Jerusalem, F
    Silani, V
    Vos, PE
    Wokke, JHJ
    Dobbins, T
    [J]. NEUROLOGY, 1998, 51 (02) : 583 - 586
  • [5] Borg K, 1996, Neuromuscul Disord, V6, P75, DOI 10.1016/0960-8966(95)00013-5
  • [6] SERUM INSULIN-LIKE GROWTH FACTOR-I LEVELS IN AMYOTROPHIC-LATERAL-SCLEROSIS
    BRAUNSTEIN, GD
    REVICZKY, AL
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1987, 50 (06) : 792 - 794
  • [7] El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis
    Brooks, BR
    Miller, RG
    Swash, M
    Munsat, TL
    [J]. AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS, 2000, 1 (05): : 293 - 299
  • [8] Neurodegeneration is associated to changes in serum insulin-like growth factors
    Busiguina, S
    Fernandez, AM
    Barrios, V
    Clark, R
    Tolbert, DL
    Berciano, J
    Torres-Aleman, I
    [J]. NEUROBIOLOGY OF DISEASE, 2000, 7 (06) : 657 - 665
  • [9] Carro E, 2000, J NEUROSCI, V20, P2926
  • [10] Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis
    Dalton, CM
    Brex, PA
    Miszkiel, KA
    Hickman, SJ
    MacManus, DG
    Plant, GT
    Thompson, AJ
    Miller, DH
    [J]. ANNALS OF NEUROLOGY, 2002, 52 (01) : 47 - 53